Question: Please describe this drug.
 The Molecule has the SMILES O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)O)c1.
Answer: Gozetotide is an unlabeled radiotracer composed of the human prostate specific membrane antigen (PSMA)-targeting ligand and linked to the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), that may potentially be used to prevent or reduce salivary gland toxicities of PSMA-targeted radionuclides. Upon administration of gozetotide into the salivary gland, gozetotide may selectively decrease salivary uptake of systemically administered PSMA-targeted radionuclides. This may reduce the salivary gland toxicities of these agents including salivary gland hypofunction and xerostomia.
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)O)c1
C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)O)CC(=O)O)CC(=O)O)O
(2S)-2-[[(1S)-1-carboxy-5-[6-[3-[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]methyl]-4-hydroxyphenyl]propanoylamino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid
Please describe this drug.
Gozetotide is an unlabeled radiotracer composed of the human prostate specific membrane antigen (PSMA)-targeting ligand and linked to the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), that may potentially be used to prevent or reduce salivary gland toxicities of PSMA-targeted radionuclides. Upon administration of gozetotide into the salivary gland, gozetotide may selectively decrease salivary uptake of systemically administered PSMA-targeted radionuclides. This may reduce the salivary gland toxicities of these agents including salivary gland hypofunction and xerostomia.